All In Biotech

Drug Trial Radar · NCT05569382

Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy

Last checked: Nov 20, 2026Latest source record: Mar 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Aug 10, 2022

Primary completion

Apr 1, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Morten Steen Kvistholm JensenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Viborg Regional Hospital; Zealand University Hospital; Odense University Hospital
First posted
Oct 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Aim: to compare the treatment effects of Bisoprolol (beta 1 receptor specific beta blocker (BB)) and Verapamil (cardio-specific calcium channel blockers (CCB)) in patients with non-obstructive hypertrophic cardiomyopathy (HCM). Background: Hypertrophic cardiomyopathy (HCM) is characterized by hypertrophy of the left ventricular wall and a hypercontracted state of the sarcomeres. This narrows the left ventricular cavity, but though the left ejection fraction is increased the stroke volume and the cardiac output cannot be fully compensated. The disease manifestations can be mild or develop into severe functional limitations and devastating complications at early age. Dyspnea, chest pain, palpitations and syncope are the most common symptoms, and patients are at risk of supraventricular and ventricular arrhythmias. Arrhythmias and sudden cardiac deaths may precede heart failure symptoms. Patients with symptomatic HCM are treated initially with beta blockers and calcium channel blockers. However, there is limited evidence supporting the effectiveness of this guideline-recommended treatment in HCM. Methods: The study is a multicenter, double-blinded, randomized, placebo-controlled cross-over trial. Patients are randomized in to three 35-days treatment periods with Bisoprolol, Verapamil and Placebo. Each treatment period includes a 7-days up titration period, a 21-days target dose period and a 7-days down titration period. Between treatment periods 45 days treatment pause is allowed. End point will be evaluated at day 21 (- 4 days). Patients will be evaluated by cardiopulmonary exercise test, echocardiography, 7 day Holter-monitoring, biomarkers and the Kansas City Cardiomyopathy Questionnaire (KCCQ). A subgroup of patients will also be evaluated with cardiac magnetic resonance imaging. Hypotheses: Three separate phases each with one primary effect parameters will be analyzed between treatment with Bisoprolol and Verapamil: Phase 1: The maximal oxygen consumption (VO2 max) is different (ΔVO2 max ≥1 ml/kg/min) between treatments in non-obstructive HCM patients Phase 2: The left ventricular enddiastolic volume (LVvol) is different (ΔLVvol ≥3 ml) between treatments in non-obstructive HCM patients. Phase 3: The incidence of non-sustained ventricular tachycardia (NSVT) is different (Hazard ratio ≥ 0.5) between treatments in non-obstructive HCM patients. The trial will be performed and analyzed in three phases, and each phase may be unblinded and analyzed separately.

Conditions

  • Non-obstructive Hypertrophic Cardiomyopathy

Interventions

  • VerapamilDrug

    1\. week: uptitration with 120 mg capsules per day, until maximum dosage of 360 mg´s/day. 2-4. week: steady state treatment with the maximum tolerated dose. 5\. week: downtitration

  • BisoprololDrug

    1\. week: uptitration with 2.5 mg capsules per day, until maximum dosage of 7.5 mg´s/day. 2-4. week: steady state treatment with the maximum tolerated dose. 5\. week: downtitration

  • PlaceboDrug

    1\. week: uptitration with one capsules per day, until maximum dosage of three capsules/day. 2-4. week: steady state treatment with the maximum tolerated dose. 5\. week: downtitration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximal oxygen consumption (VO2 max)Time frame: Changes will be evaluated at day 21 in each treatment arm
  2. Left ventricular enddiastolic volume (LVvol)Time frame: Changes will be evaluated at day 21 in each treatment arm
  3. Incidence of non-sustained ventricular tachycardia (NSVTTime frame: Changes will be evaluated at day 21 +7 days in each treatment arm

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Cardiology, Aarhus University Hospital

    Aarhus N, Denmark · Recruiting

  • Department of Cardiology, Odense University Hospital

    Odense, Denmark · Recruiting

  • Department of Cardiology, Zealand University Hospital

    Roskilde, Denmark · Not yet recruiting

  • Department of Cardiology, Regional Hospital Viborg

    Viborg, Denmark · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.